INTRODUCTION {#sec1-1}
============

Molecular techniques are more and more significant in daily cytology practice.\[[@ref1]\] In particular, the demonstration of specific oncogenic mutations is a relevant diagnostic and predictive tool.\[[@ref1]\] As an example, the assessment of *KRAS* mutational status may be useful to refine uncertain cytological diagnoses of solid pancreatic lesions\[[@ref2]\] and to differentiate mucinous from nonmucinous cysts.\[[@ref3]\] Moreover, metastatic colorectal cancer (mCRC) patients harboring *KRAS* mutations at codons 12 and 13 in exon 2, codons 59 and 61 in exon 3, and codons 117 and 146 of exon 4 do not benefit from the administration of EGFR antagonists.\[[@ref4]\] In routine practice, *KRAS* testing is usually performed on resected primary tumor samples of CRC, but the cytological sampling of the metastatic sites is useful when there is complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer\[[@ref5]\] and to serially monitor for the emergence of mutant treatment resistant clones.\[[@ref6][@ref7]\]

In both pancreatic and colorectal cancer patients, *KRAS* testing should have a fast turnaround testing, in line with the need of urgent clinical actions. Thus, instead of outsourcing cytological samples to a small number of referral molecular pathology laboratories, *KRAS* testing may be carried out in the same center where the patient is diagnosed. Unfortunately, the competence needed to validate and run complex molecular diagnostic assays is beyond most cytopathology laboratories.\[[@ref8]\] However, the automated allele-specific real-time polymerase chain reaction (RT-PCR) technology is advancing at rapid pace. In particular, the fully automated molecular diagnostics system Idylla™ (Biocartis, Mechelen, Belgium) is a fascinating technology.\[[@ref9][@ref10][@ref11]\] Sample preparation is combined with PCR thermocycling and fluorescence detection of target sequences. Without needing highly skilled staff, within approximately 90 min, the Idylla™ mutational tests approved for *in vitro* diagnostic use by the European Community (CE-IVD) marked can genotype *KRAS* with 5% detection limit, enabling method standardization even in those diagnostic units without molecular infrastructures.\[[@ref12]\] Although the Idylla™ tests were designed for use with formalin-fixed paraffin-embedded (FFPE) sections, as we previously have shown the Idylla™ system can also process DNA preparations obtained from fresh cells.\[[@ref12]\] The aim of this study was to assess Idylla™ performance on the DNA extracted from archival smears of pancreatic and mCRC.

MATERIALS AND METHODS {#sec1-2}
=====================

Study cases {#sec2-1}
-----------

The database of the Cytopathology Department at the University of Naples was searched to select archival smears of pancreatic cancer (*n* = 10) and metastatic adenocarcinoma of colorectal origin (*n* = 11). The smears were reviewed by two qualified pathologists, EV and MdA, and the diagnosis was confirmed, and in all cases, the purity of tumor cells was estimated as a percentage of malignant cells out of the total nucleated cells. Since the analytic sensitivity of the Idylla test is high (5% of mutant allele detection), cases were selected without a specific requirement of neoplastic cellularity. Archival smears were processed between March and May 2016. A single slide was retrieved for each case. Each slide was incubated in xylene for 3 days to allow coverslip removing and air-dried; tumor cells were scraped off directly from the whole glass surface. Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Crawley, West Sussex, UK) and quantified (ng/µl) as previously described.\[[@ref13]\] All cases were tested by Idylla regardless from the DNA concentration.

Since *KRAS* mutational analysis is part of the routine diagnostic workup of patients with pancreatic and colorectal lesions, the need for Ethic Committee\'s approval was not necessary for this study, in accordance with Medical Ethical Guidelines of the University Federico II Medical School. Accordingly to these guidelines, a comprehensive written informed consent was signed for the procedure (fine needle aspiration) that produced the tissue samples. All information regarding the human material was managed using anonymous numerical codes. All samples were handled in compliance with the Declaration of Helsinki (<http://www.wma.net/en/30publications/10policies/b3/>).

The Idylla™ system {#sec2-2}
------------------

The Idylla system is an automated platform for the detection of genetic mutations based on qualitative allele-specific RT-PCR.\[[@ref9][@ref10][@ref11]\] The apparatus features a sample preparation module integrated with a combined PCR thermocycling and fluorescence detection module. All consumables required to perform sample preparation and RT-PCR detection are provided in disposable cartridges that are loaded onto the Idylla system to enable the simultaneous detection of up to 30 molecular targets. Closing of the cartridge after inserting the sample avoids cross contamination.

The Idylla™ *KRAS* mutation test {#sec2-3}
--------------------------------

The Idylla™ *KRAS* mutation test is a single-use cartridge-based test. Through microfluidic channels in the cartridge, nucleic acids are transported into five separate PCR chambers, which contain predeposited PCR reagents in dried form (i.e., primers, probes, enzymes) designed for the qualitative detection of 21 *KRAS* mutations and including *KRAS* total (wild-type gene acting as sample processing control).

Seven mutations are targeted in exon 2: p.G12C (c.34G\>T), p.G12R (c.34G\>C), p.G12S (c.34G\>A), p.G12A (c.35G\>C), p.G12D (c.35G\>A), p.G12V (c.35G\>T), and p.G13D (c.38G\>A). Nine mutations can be detected in exon 3: p.A59E (c.176C\>A), p.A59G (c.176C\>G), p.A59T (c.175G\>A), p.Q61K (c.181C\>A; c.180_181TC\>AA), p.Q61 L (c.182A\>T), p.Q61R (c.182A\>G), and p.Q61H (c.183A\>C; c.183A\>T); whereas five mutations are targeted in exon 4: p.K117N (c.351A\>C; c.351A\>T), p.A146P (c.436G\>C), p.A146T (c.436G\>A), and p.A146V (c.437C\>T).

To perform the analysis, 10 ng of extracted genomic DNA was directly pipetted inside an Idylla *KRAS* mutation test cartridge. This latter was, then, loaded into the Idylla instrument. The fully automated analysis required approximately 2 h. The Idylla console autoanalyzed the PCR curve to determine the presence or absence of a *KRAS* mutation and the results were presented on screen as either "no mutation detected" or "*KRAS* mutation detected," indicating the specific mutation.

To assess the Idylla *KRAS* mutation test performance, in any single case, extracted DNA was run in parallel by the CE-IVD marked Easy *KRAS* kit (Diatech Pharmacogenetics, Jesi, Italy) on a QuantStudio 5 instrument (Thermo Fisher, Monza, Italy).\[[@ref14]\] This commercially available test detects all relevant mutations of exon 2, 3, and 4 of *KRAS* by standard RT-PCR.

RESULTS {#sec1-3}
=======

Idylla yielded valid results in 18/21 (85.7%) samples \[[Table 1](#T1){ref-type="table"}\] in a first run. Three samples, whose DNA concentration was \<0.5 ng/µl, gave an invalid result. Only one of these cases was successfully amplified by the Easy *KRAS* kit, resulting wild type. On the overall, the group of 18 cases, was equally composed (*n* = 9) by pancreatic and mCRC smears. Papanicolaou-stained smears were more frequent (*n* = 11) than Diff-Quik-stained smears (*n* = 7). A total of 11 cases showed a *KRAS* mutation, and a representative example is reported in [Figure 1](#F1){ref-type="fig"}. In all cases, the Easy *KRAS* kit confirmed the obtained results \[[Table 1](#T1){ref-type="table"}\]. In particular, the mutations detected by both techniques were the following: p.G12D (*n* = 4), p.G12V (*n* = 2), p.G12R (*n* = 1), p.G13D (*n* = 1), p.A59E/G/T (*n* = 2), p.Q61H (*n* = 1). Four mutant cases (p.G12D, p.G12R, p.G12V, and p.Q61H) were observed in the group of pancreatic smears, whereas seven mCRC smears harbored a *KRAS* mutation (*n* = 3 p.G12D; *n* = 2 p.A59E/G/T; *n* = 1 p.G12V; *n* = 1 p.G13D). The absence of mutations in five pancreatic and two mCRC smears was also confirmed by Easy *KRAS* kit. Noteworthy, most of the wild-type pancreatic cancer featured a low cellularity with the presence of \<20% of cancer cells.

###### 

Idylla KRAS performance on DNA extracted from 18 archival smears
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![Example of concordant molecular results in a *KRAS* exon 2 mutated sample (case \#8, [Table 1](#T1){ref-type="table"}). Archival DNA was extracted from a Diff-Quik-stained smear of pancreatic cancer featuring 50% of neoplastic cells and a concentration of 3, 57 ng/μl. Representative graphs of standard real-time polymerase chain reaction and Idylla are reported both showing G12R *KRAS* mutation](CJ-14-5-g002){#F1}

DISCUSSION {#sec1-4}
==========

On pancreatic fresh cells, collected by fine-needle aspiration and directly immersed in a tube with a preserving buffer, Idylla™ *KRAS* test showed a clinical sensitivity higher than Sanger sequencing.\[[@ref12]\] Similar to that observed on pancreatic fresh cells, also on archival smears, the Idylla™ *KRAS* test performance is high and similar to that of Easy *KRAS* kit. In fact, the two methods showed a complete concordance, alleviating the concern of possible false negative results by Idylla. According to manufacturer, the minimum tumor percentage to avoid false negative results is 10%. Thus, there was only one case (\#2) with really low tumor (5%) that does not rule out the possibility of false negative results by Idylla. However, recent cell line dilution data showed that the EGFR L858R point mutation can be detected by Idylla even at 1% dilution.\[[@ref15]\]

Noteworthy, the rate of wild-type pancreatic adenocarcinoma was higher than the documented rates in most other published series.\[[@ref1]\] This may reflect the limited number of cases tested but may also be explained by the low (\<20%) neoplastic cellular content of most (4/5) cases. In addition, due to the stochastic distribution of benign and malignant cells, in these cases, manual microdissection to enrich for neoplastic cells was unfeasible, leading to a further dilution of potentially present mutant alleles. These limitations may be overcome by the more sensitive next-generation sequencing,\[[@ref16]\] whose implementation is cost-effective only in large volume centralized laboratories.\[[@ref17]\] Conversely, we showed that Idylla may be easily adopted by a large number of cytopathology laboratories.

Only three cases yielded an invalid result that was likely due to insufficient DNA (\<0.5 ng/µl). Although this system has obtained the CE-IVD mark for FFPE material, the extracted DNA from routine smears can be directly pipetted into the cartridge, which may be automatically run as if an FFPE sample had been inserted. This off-label use of the Idylla test should not be seen as limiting factor since it is the same use of direct smears that classifies the procedure as a laboratory developed test, requiring in-house validation and quality control monitoring.

The time required to genotype DNA for *KRAS* mutational status assessment is approximately 2 h, compensating for the high cost related to the CE-IVD mark of a single cartridge (\~€150). Although the process of removing the coverslip of archival smears does not compromise the quality of the DNA, it is time-consuming. In this study, smears archived for at least 2 years were employed, requiring even 3 days, but to avoid any delay, rapid on-site evaluation, at the time of the FNA procedure, enables the best triage of the sample for diagnosis and ancillary studies and the selection of a representative slide, that it is maintained uncoverslipped for immediate DNA extraction and Idylla processing.\[[@ref1]\] Our results, showing that mCRC smears can reliably be tested by Idylla for *KRAS* mutation, and the recent availability of Idylla *NRAS*/*BRAF* test can give the cytopathologist the opportunity to sample metastatic sites to perform molecular analysis on cytological smears when histological resections are not available or when the patient is monitored to early detect the arising of mutant-resistant clones.\[[@ref6]\]

CONCLUSION {#sec1-5}
==========

This study demonstrates that the fully automated molecular diagnostics system Idylla™ is a promising opportunity for *KRAS* mutation testing on cytological samples. Even in less experienced laboratories, the cytopathologist may easily integrate morphological diagnostic report with accurate molecular information relevant for diagnostic and treatment decisions. However, it should be born in mind that long-term experiences are required to assess the feasibility of this automated molecular diagnostics system, and specific educational programs are required to enable pathologists to review and sign out clinical molecular genetic/molecular pathology results, and meanwhile, the relevance of a staff board-certified molecular pathologist or clinical molecular geneticist cannot be overemphasized.
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BRAF - v-raf murine sarcoma viral oncogene homolog B;

CE - IVD - *In Vitro* Diagnostic Medical Devices in Europe;

DNA - Deoxyribonucleic acid;

EGFR - Epidermal Growth Factor Receptor;

FFPE - Formalin Fixed Paraffin Embedded;

KRAS - Kirsten ras oncogene homolog;

mCRC - metastatic Colo -- Rectal Cancer;

NRAS - Neuroblastoma RAS Viral Oncogene Homolog;

RT-PCR - Real Time Polimerase Chain Reaction.
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